AletheiaHQ
Sign In
DIR-B9-3DK-PKPC/LVL 2·Guided ArbitrageGuided multi-step solo arbitrage producing a concrete deliverable. Requires basic commercial judgment. Examples: formatting extracted data into a $99 compliance checklist and cold-emailing 500 affected businesses; translating a buried scientific abstract into a viral short-form script monetised via affiliate links./90% confidence
Return to Directory

Extract OUTFLOWGEN Corporate Dossier via Public Registry Scrape

Organization
OUTFLOWGEN LLC (NIH-funded startup with fragmented public records)
Sector
Pharma business development teams and early-stage biotech investors
Location
Portland, OR

Source Reference

https://reporter.nih.gov/project-details/1R41EY039138-01

// Venture Capital// Grantmaking Foundations// Biotech// Data Scraping// IP// Open-Source Intelligence// Health Policy & Regulation// Data Engineering & Pipelines

Executive Context

NIH awarded $311,049 Phase I STTR funding to OUTFLOWGEN LLC for a first-in-class CRISPR glaucoma therapy, creating a predictable commercial gap where scientific validation exists but commercialization infrastructure is absent. The structural asymmetry is between NIH's ability to fund early science and small biotechs' inability to navigate the regulatory and capital requirements for clinical development.

Catalyst / Timing

NIH-funded startups like OUTFLOWGEN LLC exist in information voids—pharma BD teams cannot quickly assess their corporate structure, IP position, or funding timeline without manual research. The data exists across multiple public registries but isn't consolidated.

Projected Yield

$500-1,500 per dossier sold to pharma BD teams or investors

Structural Friction

• Vulnerability: NIH-funded startups like OUTFLOWGEN LLC exist in information voids—pharma BD teams cannot quickly assess their corporate structure, IP position, or funding timeline without manual research. The data exists across multiple public registries but isn't consolidated. • Capital yield: $500-1,500 per dossier sold to pharma BD teams or investors • Resource capture: Proprietary database of early-stage biotech corporate structures • Influence capture: First-mover intelligence position on emerging NIH-funded gene therapy startups • Required vectors: Vector: OSINT & Public Records Research

Required Capabilities

  • Vector: OSINT & Public Records Research

    Primary executor: Phase 1: Corporate & IP Reconnaissance: Search Oregon Secretary of State business registry for OUTFLOWGEN LLC filing det

Execution Protocol

Execution Protocol Locked

A one-time payment of $49 unlocks the exact wedge, required assets, and step-by-step execution parameters yours forever, no subscription.

This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.